Sit Investment Associates’s Pacific Biosciences PACB Stock Holding History

Sit Investment Associates’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-43,450	Closed	-$395K	–	526
2022 Q1	$395K	Sell	43,450 -38,100	-47%	-$439K	0.01%	425
2021 Q4	$1.67M	Hold	81,550	–	–	0.04%	329
2021 Q3	$2.08M	Hold	81,550	–	–	0.05%	290
2021 Q2	$2.85M	Hold	81,550	–	–	0.07%	259
2021 Q1	$2.72M	Sell	81,550 -71,425	-47%	-$2.5M	0.07%	272
2020 Q4	$3.97M	Sell	152,975 -23,200	-13%	-$394K	0.11%	230
2020 Q3	$1.74M	Buy	+176,175	New	+$1.01M	0.05%	293

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Sit Investment Associates's PACB Position: Q2 2022 in Review

Sit Investment Associates sold out of Pacific Biosciences (PACB) in Q2 2022, closing a stake of 43,450 shares — an estimated $395K sold.

Sit Investment Associates first reported a position in PACB in Q3 2020 and held it in 7 quarters. The position peaked at $3.97M in Q4 2020. 229 funds tracked by Wall St. Rank hold PACB as of Q2 2022.

Sit Investment Associates reported no remaining Pacific Biosciences position as of Q2 2022 after selling out during the quarter.
Sit Investment Associates sold 43,450 Pacific Biosciences shares in Q2 2022, an estimated $395K.
Sit Investment Associates first reported a position in Pacific Biosciences in Q3 2020 and held it in 7 quarters.
Sit Investment Associates's Pacific Biosciences position peaked at $3.97M in Q4 2020.
229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2022.

Based on Sit Investment Associates's 13F filing for Q2 2022, filed 11 Aug 2022.